Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus

Drugs

Volumn 62, Issue 12, 2002, Pages 1805-1837

  Wagstaff, Antona J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Pharmacodynamics; Pharmacokinetics; Rosiglitazone; Therapeutic use; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA;

ANEMIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMETHYLATION; DIABETIC DIET; DISEASE MARKER; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; LIVER DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0036343675     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262120-00007     Document Type: Review

References (207)

1. Insulin resistance: Current therapeutic approaches
2. PPARγ agonists in type 2 diabetes: How far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone
3. Thiazolidinediones
4. Thiazolidinediones: A new class of antidiabetic drugs
5. Differentiating members of the thiazolidinedione class: A focus on safety
6. Rosiglitazone
7. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with anti-diabetic actions in db/db mice
8. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
9. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes
10. Peroxisome proliferator-activated receptors in the cardiovascular system
11. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans
12. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ
13. Differential activity of rosiglitazone enantiomers at PPARγ
14. Phase I metabolites of rosiglitazone and pioglitazone are ligands for PPARγ but not PPARα; ENDO
15. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation
16. Thiazolidinediones promote human pre-adipocyte differentiation and activate hPPARγ
17. Depot-related and thiazolidinedione-responsive expression of uncoupling protein 2 (UCP2) in human adipocytes
18. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
19. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes
20. The expression of the p85α subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor γ in human adipocytes
21. Differential regulation of UCP-1 expression by rosiglitazone and Wy 14643 in brown adipocytes
22. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes
23. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells
24. Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes
25. Thiazolidinediones and insulin resistance: Peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene
26. Cloning and characterization of a functional peroxisome proliferator activator receptor-γ-responsive element in the promoter of the CAP gene
27. PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
28. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia
29. Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway
30. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression
31. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension
32. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients
33. Unraveling the mechanism of action of thiazolidinediones
34. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
35. Mechanisms by which rosiglitazone improves glycaemic control in type 2 diabetes
36. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone
37. Comparison of the glucose and lipid effects of rosiglitazone and pioglitazone following conversion from troglitazone treatment
38. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice
39. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records
40. Pharmacologic therapy for type 2 diabetes mellitus
41. Prior treatment of obese Zucker rats with the thiazolidinedione (BRL 49653) decreases insulin resistance in perfused hindlimb
42. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
43. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes: Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling
44. Insulin-sensitising action of rosiglitazone is enhanced by food restriction
45. Insulin sensitising effect of rosiglitazone: Effects on metabolism and gene expression
46. Rosiglitazone may reduce insulin resistance related cardiovascular disease risk in patients with type 2 diabetes
47. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes
48. Rosiglitazone increases insulin sensitivity and reduces factors associated with insulin resistance in type 2 diabetics
49. Effects of thiazolidinediones on lipoprotein subclasses in patients who are insulin resistant
50. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat
51. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
52. Novel euglycemic and hypolipidemic agents
53. Avandia Worldwide Awareness Registry: Improved metabolic control with initiation of rosiglitazone in a diabetes clinic setting
54. Differing effects of thiazolidinediones on LDL subfractions
55. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes
56. Differing effects of thiazolidinediones on HDL subfractions and LP(a)
57. Combined effects of rosiglitazone and atorvastatin on the dyslipidaemia associated with type 2 diabetes
58. Pioglitazone versus rosiglitazone therapy in randomized follow-up in patients previously treated with troglitazone
59. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
60. Rosiglitazone monotherapy is effective in patients with type 2 diabetes
61. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone
62. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart
63. 2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury
64. Rosiglitazone prevents the development of hyperglycemia and hyperinsulinemia and significantly reduces neointimal formation following carotid wire injury in APOE (-/-) mice fed a western diet
65. Rosiglitazone reduces atherosclerosis in ApoE KO mice
66. Rosiglitazone: No effect on erythropoiesis or premature red cell destruction
67. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose-level lowering
68. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
69. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
70. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus
71. Expression and function of PPARγ in rat and human vascular smooth muscle cells
72. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes
73. BRL 49653 (a thiazolidinedione) is well tolerated and has no effect on LV mass following 12 weeks treatment in NIDDM patients
74. Rosiglitazone: Cardiac safety with long-term treatment in patients with type 2 diabetes
75. Effect of diabetes and rosiglitazone on myocardial blood flow
76. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human subcutaneous adipocytes
77. Rosiglitazone in combination with glibenclamide: Effect on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes
78. Evidence of a potent anti-inflammatory effect of rosiglitazone in mononuclear cells
79. Effects of rosiglitazone treatment on levels of C-reactive protein and MMP9 in patients with type 2 diabetes
80. The effect of treatment with rosiglitazone on C-reactive protein and interleukin-6 in patients with type 2 diabetes
81. Rosiglitazone influences macrophage function but not monocyte/macrophage differentiation
82. BRL 49653, a new insulin-sensitizing agent, protects against impairment of endothelial function in Zucker fatty rats
83. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor
84. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
85. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro
86. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes
87. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
88. Standards of medical care for patients with diabetes mellitus
89. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes
90. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes
91. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y
92. Therapeutic index for rosiglitazone in dietary obese rats and effects on body weight and plasma leptin
93. Therapeutic index for rosiglitazone in dietary obese rats: Separation of efficacy and haemodilution
94. The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-γ and aPd2 in adipose tissue of high-fat-fed rats
95. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ
96. Troglitazone and emerging glitazones: New avenues for potential therapeutic benefits beyond glycemic control
97. Rosiglitazone reduces hepatic fat and increases subcutaneous but not intra-abdominal fat depots
98. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus
99. Rosiglitazone treatment reduces gamma-glutamyltransferase levels, a marker for visceral and hepatic fat
100. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes
101. Toxicity of troglitazone in cultured rat hepatocytes
102. Evaluation of liver function in type 2 diabetic patients during clinical trials
103. Rosiglitazone therapy is not associated with hepatotoxicity
104. A diabetes outcome progression trial (ADOPT) of long-term rosiglitazone, metformin, and glyburide monotherapy in drug-naive patients
105. Rosiglitazone increases pancreatic islet area, density and insulin content, but not insulin gene expression
106. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content
107. The PPARγ agonist, BRL 49653, prevents onset of hyperglycemia and proteinuria in ZDF rats
108. Beta-cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death
109. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes mellitus
110. Rosiglitazone alone or in combination with metformin gives long-term glycemic control
111. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes
112. Rosiglitazone reduces plasma insulin and its precursors while decreasing glycaemia in patients with type 2 diabetes
113. Rosiglitazone is effective in obese and non-obese patients with type 2 diabetes
114. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans
115. Population pharmacokinetics of rosiglitazone in phase III clinical trials
116. Systemic exposure to rosiglitazone is unaltered by food
117. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
118. Effect of renal impairment on the pharmacokinetics of rosiglitazone (RSG)
119. Pharmacokinetics of rosiglitazone are unaltered in hemodialysis patients
120. Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG)
121. A study of the effect of age on the pharmacokinetics of BRL 49653C in healthy volunteers
122. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone
123. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics
124. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers
125. Rosiglitazone does not alter the pharmacokinetics of metformin
126. The effect of acarhose on the pharmacokinetics of rosiglitazone
127. Rosiglitazone pharmacokinetics are not affected by coadministration of ranitidine
128. Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin
129. Rosiglitazone in combination with an HMG CoA reductase inhibitor: Safety and effects on lipid profile in patients with type 2 diabetes
130. Rosiglitazone treatment does not impair the triglyceride-lowering activity of fibrates in patients with type 2 diabetes mellitus
131. Rosiglitazone does not increase the risk of alcohol-induced hypoglycemia in diet-treated type 2 diabetics
132. Standards of medical care for patients with diabetes mellitus
133. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus
134. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes
135. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study
136. Rosiglitazone monotherapy significantly lowers HbA1c levels in treatment- naive type 2 diabetic patients
137. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose in type 2 diabetic patients
138. Rosiglitazone is an effective alternative to glibenclamide as first-line therapy in type 2 diabetic patients
139. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)
140. Efficacy and safety of rosiglitazone combined with glibenclamide is effective and well tolerated in type 2 diabetes patients inadequately controlled on maximum-dose glibenclamide
141. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
142. Rosiglitazone-metformin combination improves glycemic control in patients with type 2 diabetes
143. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
144. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
145. Repaglinide/rosiglitazone combination therapy of type 2 diabetes
146. Rosiglitazone: Long-term efficacy in combination with metformin or as monotherapy
147. Rosiglitazone in combination with glibenclamide plus metformin is effective and well tolerated in type 2 diabetes patients
148. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus
149. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes
150. Rosiglitazone is effective in patients of Indo-Asian ethnic origin with type 2 diabetes
151. Rosiglitazone is effective and well tolerated as monotherapy in African Americans with type 2 diabetes
152. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulfonylureas
153. Rosiglitazone in combination with sulphonylurea improves glycemic control in Chinese type 2 diabetes patients
154. Rosiglitazone is effective and well tolerated in patients ≥65 years with type 2 diabetes
155. Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes
156. Rosiglitazone: Effective when added to metformin in obese, insulin- resistant patients with type 2 diabetes
157. Effects of rosiglitazone to improve glycemic control in type 2 diabetes patients taking β-blockers
158. Rosiglitazone added to a sulphonylurea: Effective and well tolerated in patients with type 2 diabetes and mild to moderate renal impairment
159. Rosiglitazone is effective in poorly controlled type 2 diabetes patients
160. Pulmonary edema associated with rosiglitazone and troglitazone
161. SB/Bristol Avandia lipid adverse effect diminishes over two months - Label
162. Hepatocellular injury in a patient receiving rosiglitazone. A case report
163. Hepatic failure in a patient taking rosiglitazone
164. Rosiglitazone toxicity
165. Isolated elevation of alkaline phosphatase level associated with rosiglitazone
166. Liver failure in a patient treated with long-term rosiglitazone therapy
167. Rosiglitazone and hepatic failure
168. Rosiglitazone has a favorable safety profile in Chinese type 2 diabetics with previous exposure to hepatitis B or C infection
169. European Union market news
170. Avandia launched in UK and Germany
171. Rosiglitazone approved for treatment of type 2diabetes [news]
172. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections
173. A risk-benefit assessment of metformin in type 2 diabetes mellitus
174. European DPG1. A desktop guide to type 2 diabetes mellitus
175. Lifestyle intervention reduces multiple risk factors in obese patients with poorly controlled insulin-requiring type 2 diabetes mellitus
176. The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus
177. Some answers, more controversy, from UKPDS
178. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
179. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
180. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes
181. European study of impact of rosiglitazone on CVD
182. Economic comparison of six first-line drug strategies in type 2 diabetes using a Monte Carlo simulation model
183. Cost-effectiveness and cardiovascular risk an analysis of rosiglitazone compared with other oral hypoglycemic agents in the treatment of type 2 diabetes mellitus
184. The cost of managing diabetes mellitus: Focus on the oral pharmacologic management of type II diabetes
185. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care
186. Costs and quality-of-life issues of type 2 diabetes mellitus
187. Recent developments and emergingtherapies for type 2 diabetes mellitus
188. Rosiglitazone for type 2 diabetes mellitus
189. Repaglinide and diabetes: No better than glucose-lowering sulphonamides
190. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes
191. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial
192. Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus
193. Mounting dissatisfaction with NICE in the UK
194. Insulin manufacturer expresses concerns over NICE guidance
195. NICE guidance for type 2 diabetes too confusing?
196. Novo Nordisk says NICE diabetes guidance causes grave concern
197. Pioglitazone
198. Guidance on rosiglitazone for type 2 diabetes mellitus
199. Rosiglitazone and type 2 diabetes mellitus